Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study

Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients treated with HYMPAVZI showed a 93% reduction in the annualized bleeding rate (ABR) compared to OD therapy. Management noted that HYMPAVZI is administered only once a week through subcutane ...